MOUNTAIN VIEW, Calif., Nov. 27 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the Company will present at the following upcoming investor conferences on November 28th and December 12th, 2007 in New York City:
A live webcast of the presentations will be available on the Investor Relations section of MAP Pharmaceuticals’ website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals, Inc. uses proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. The Company has several proprietary product candidates in clinical development that address large market opportunities, including its two most advanced product candidates, a proprietary formulation of nebulized budesonide for the potential treatment of children with asthma, and a proprietary formulation of inhaled dihydroergotamine for the potential treatment of migraine, as well as a proprietary combination of an inhaled corticosteroid and a long-acting beta2-agonist for the potential treatment of asthma and chronic obstructive pulmonary disease. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., +1-650-386-3122,
ljohnson@mappharma.com
Web site: http://www.mappharma.com/
